News

Up to six years of treatment with Livmarli (maralixibat), which is approved for reducing itch, or pruritus, in Alagille syndrome, prolonged survival and…

A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…

Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown to normalize liver biomarkers and…

Women with intrahepatic cholestasis of pregnancy (ICP) show lesser diversity across their gut bacteria than do other pregnant women, a study reports. Its findings…

Weekly injections under the skin of the experimental therapy survodutide significantly reduces the severity of metabolic-associated steatohepatitis (MASH), a severe form of fatty…

The composition of microbes is altered in the intestines of infants with biliary atresia, a type of liver disease that affects the bile ducts,…

While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…

Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…

Bortezomib, an anticancer medication, prevented a recurrence of progressive familial intrahepatic cholestasis type 2 (PFIC2) after a liver transplant by helping a young girl…

Most liver transplant centers in the U.S. continue to use stigmatizing language on their websites that could make people with alcohol-associated liver disease (ALD)…